Background {#Sec1}
==========

The National Center for Complementary and Integrative Health, the federal government's lead agency for scientific research on complementary and alternative medicine (CAM), defines CAM as a category of medicine that includes a variety of treatment approaches that fall outside the realm of conventional medicine. CAM therapies have been grouped into five distinct domains: manipulative and body-based methods, biological treatments, mind-body interventions, energy therapies, and alternative medical systems \[[@CR1]\]. Evidence from national studies suggest that approximately one-third of Americans used some form of CAM in the past 12 months \[[@CR2]\]. Use of non-conventional medicine in the general population has been increasing in the past decade and contributes substantially to health care spending. In 2007, Americans spent nearly \$34 billion in out-of-pocket expenses on CAM, which represented a 25% increase in spending compared earlier estimates from 1997 trends \[[@CR3]\].

A substantial body of research has focused on understanding trends and patterns of CAM use in the general U.S. population \[[@CR2], [@CR4]\], as well as among specific patient subgroups. Several studies have examined correlates and predictors of CAM use among patients with specific chronic diseases, including diabetes \[[@CR5]\], cancer \[[@CR6]\], and cardiovascular disease \[[@CR7]\], with evidence suggesting high CAM use among patients with chronic illness. Despite advances in the collective understanding of CAM use among patients with chronic illness, little is known about the utilization of CAM among patients with multiple chronic conditions. Although more than a quarter of Americans are estimated to have multiple comorbidities, we identified few studies \[[@CR8]\] assessing the effect of specific combinations of chronic diseases (dyads and triads) on use of CAM. Notably, none of these studies focused specifically on patients with cardiovascular risk factor combinations such as hypertension, hypercholesterolemia, diabetes, and obesity, all of which are conditions of increasing prevalence and public health significance. Whereas the prevalence of hypertension among adults in the U.S. has remained relatively constant at 30% since 1999 \[[@CR9]--[@CR11]\], the prevalence of diabetes (9--12%), hypercholesterolemia (25--27%), and obesity (31--36%) has been steadily increasing in the past decade \[[@CR9]\].

Given the increasing prevalence of these risk factors and their significant contributions to cardiovascular morbidity and mortality in the U.S. \[[@CR12]\] and around the world, this is an important gap in the scientific literature. To address this gap, this study sought to: 1) estimate the prevalence and odds of CAM use among participants with major chronic diseases such as hypercholesterolemia, hypertension, diabetes, and obesity; and 2) examine the effects of chronic condition dyads and triads on the use of specific CAM modalities and treatments. We anticipate findings from this study may be useful in generating hypotheses for future research and have practical implications for family physicians and chronic disease self-management specialists.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

This cross-sectional study consists of men and women ages 18 years and older who responded to the 2012 National Health Interview Survey (NHIS), a nationally-representative surveillance system administered by the Centers for Disease Control and Prevention's National Center for Health Statistics (NCHS). The NHIS serves as "the principal source of information on the health of the civilian non-institutionalized population in the United States." \[[@CR13]\] Beginning in 2002, the NCHS added a supplementary module on CAM utilization that is administered every five years. This study specifically focused on persons with self-reported hypercholesterolemia, hypertension, diabetes, or obesity (*n* = 15,463). The NHIS survey is a population-based surveillance system administered by the U.S. Centers for Disease Control and Prevention. The survey consists of face-to-face household interviews to obtain data for each respondent selected to complete the NHIS instrument and is administered by NCHS trained interviewers. To ensure a nationally representative data set for the civilian noninstitutionalized population of the United States, a multistage stratified sampling design is used, with interviews conducted in all 50 states and the District of Columbia. Computer-assisted data collection is utilized during each interview to perform data quality checks as responses are made and to ensure the consistency of the questionnaire flow.

The NHIS survey has several components broken down into modules. The Household module provides information on household composition and survey response characteristics. The Family module provides information on participants' relationships and family structure within households. Individual information is contained in the Person and Sample Adult modules. The Person module contains information on individual health status, health care access and utilization, health insurance, basic socio-demographics, income/assets, and family food security. The Sample Adult module contains questions on socio-demographics, health conditions/status, health behaviors, and health care access and utilization administered to randomly selected adults within the family. Finally, the Adult Alternative Medicine module provides information on the adult sample use of non-conventional health care practices. A detailed discussion of the NHIS instrument is described elsewhere \[[@CR14], [@CR15]\].

Measures {#Sec4}
--------

Overall CAM use was measured by collapsing all reported CAM products into the five domains noted previously: \[[@CR1]\] (1) manipulative and body-based methods, including chiropractic/osteopathic approaches and massage therapy; (2) biological treatments, including herbal remedies and special diets; (3) mind-body interventions, including meditation, hypnosis, prayer, and art/music therapy; (4) energy therapies, including biofield and bioelectromagnetic-based therapies, and (5} alternative medical systems, including acupuncture, Ayurvedic medicine, homeopathy, and naturopathy. A composite variable for CAM use was created by combining the domains in which CAM use was present if any one of the five domains was coded as *"1",* indicating reported CAM use within that domain. The final CAM variable was dichotomized into "0" and *"1",* where *"0"* represented absence of CAM use. The independent variables included socio-demographic and socio-economic characteristics such as age, sex, race/ethnicity, education, marital status, family income, insurance coverage, having a regular source of care, and region of residence.

Statistical analysis {#Sec5}
--------------------

The analysis consisted of descriptive statistics, bivariate analysis, and multivariate logistic regression. The descriptive analysis included counts, means, standard deviations, and proportions of CAM use. For the bivariate analysis, we performed a Chi-square test of independence to assess the association and significance of each covariate and CAM use. The multivariate logistic regression method, a critical component of the analysis, was used to assess the association between the dichotomous response variable describing CAM use and the predictor variables or covariates \[[@CR16]\]. To account for the confounding effect of the covariates in the multivariate analysis, the adjusted odds ratios (aOR) were calculated. The 95% confidence intervals for the odds ratio were determined and used not only to assess the significance of the covariates but also to determine the magnitude of the effect based on the range of the interval.

All analyses were performed using Stata 15 for Windows (STATA Corp., College Station, Texas). Data from the NHIS Family, Household, Person, Sample Adult, and Adult Alternative Medicine files were merged, and sampling weights were applied to account for the complex probability survey design \[[@CR13]\]. Using the multivariate and bivariate analysis previously described, we further stratified the analysis by disease dyads and triads across the five domains of CAM and examined the associations between the different chronic disease dyads and triads with respect to specific CAM modality use. Statistical significance was set at a *p*-value of less than 0.05.

Results {#Sec6}
=======

Table [1](#Tab1){ref-type="table"} presents descriptive statistics and the frequency of the four chronic conditions by covariates. Overall CAM use proportions in general, CAM use in participants with two or more chronic conditions, and a comparison of the adjusted odds of CAM use for those participants with one chronic condition versus two or more conditions are presented in Table [2](#Tab2){ref-type="table"} Table [3](#Tab3){ref-type="table"} provides the bivariate proportions for CAM use among disease dyads and triads for the five CAM domains. Finally, Table [5](#Tab5){ref-type="table"} summarizes statistically significant CAM domain use by disease status, including individual chronic diseases, as well as dyads and triads.Table 1Characteristics of the study sample and frequency of chronic conditions, national health interview survey, 2012CharacteristicsChronic ConditionOverall SampleHypercholesterolemiaHypertensionDiabetesObesityn(%)n(%)n(%)n(%)n(%)Age Group  \< 351241(8.0)502(39.9)823(66.6)137(11.1)490(39.8) 35--492946(18.8)1658(56.4)1860(63.1)516(17.5)1327(44.9) 50--645479(35.5)3496(63.2)3966(72.5)1338(24.0)2287(41.7)  \> 645797(37.7)3833(66.0)4649(80.2)1537(26.3)1523(26.4)Sex Male6964(44.9)4322(61.8)5045(72.5)1616(22.9)2503(35.9) Female8499(55.1)5167(60.5)6253(73.7)1912(22.3)3124(36.8)Race and Ethnicity Non-Hispanic White11,663(75.6)7423(63.4)8212(70.5)2500(21.3)4186(35.8) Non-Hispanic Black/African American2746(17.6)1377(49.7)2341(85.6)762(27.5)1199(44.2) Alaska Natives/American Indians158(1.0)86(54.1)122(78.9)53(33.7)76(50.8) Non-Hispanic Other896(5.8)603(67.4)623(69.5)213(23.3)166(18.3)Education Level Less than High School2890(18.5)1718(59.1)2291(79.6)858(29.5)1062(36.8) High School Graduate/Some College8877(57.5)5358(60.1)6589(74.3)2060(22.9)3445(38.7) College/Professional Graduate3696(24.0)2413(65.2)2418(65.4)610(16.7)1120(30.5)Marital Status Married8131(52.7)5219(64.0)5606(68.9)1778(21.8)2996(37.0) Widowed/Divorced5114(33.1)3150(61.2)4052(79.4)1293(24.7)1682(32.7) Single/Never Married2218(14.2)1120(49.9)1640(74.3)457(20.5)949(42.8)Family Income  \< \$20,0006696(43.2)3904(58.2)5322(79.6)1850(27.2)2566(38.2) \$20,000--\$34,9992107(13.8)1312(62.0)1546(73.4)460(21.9)802(38.0) \$35,000--\$49,9992306(14.9)1448(62.2)1597(69.4)473(21.0)839(36.6) \$50,000--\$74,9993435(22.3)2256(65.3)2145(62.5)544(15.6)1173(34.2) \$75,000+919(5.8)569(61.7)688(75.4)201(21.3)247(26.9)Health Insurance Coverage Yes13,742(88.8)8655(62.6)10,009(73.0)3198(23.0)4894(35.7) No1721(11.2)834(48.9)1289(74.7)330(19.3)733(42.2)Regular Source of Care Yes14,174(91.6)8836(62.1)10,389(73.4)3353(23.4)5240(37.0) No1289(8.4)653(50.7)909(70.3)175(13.5)387(30.1)Geographic Region Northeast2554(16.6)1610(62.4)1803(70.8)545(20.9)878(34.2) Midwest3206(20.8)1981(61.4)2320(72.2)694(21.3)1244(39.0) South5962(38.6)3581(59.9)4536(76.31478(24.8)2276(38.4) West3741(24.0)2317(61.9)2639(70.6)811(21.4)1229(32.5)Hypercholesterolemia Yes9489(61.1)--5853(61.8)2219(23.1)3390(35.8) No5974(38.9)--5445(91.1)1309(21.8)2237(37.3)Hypertension Yes11,298(73.2)5853(51.6)--2591(22.7)4422(39.1) No4165(26.8)3636(87.1)--937(22.4)1205(28.9)Diabetes Yes3528(22.6)2219(62.4)2591(73.4)--1722(48.9) No11,935(77.4)7270(60.7)8707(73.1)--3905(32.8)Body Mass Index  \< 18.5 (Underweight)782(5.1)451(57.8)579(73.5)178(23.0)-- 18.5--24.9 (Normal)3618(23.6)2199(60.2)2461(68.0)502(13.9)-- 25.0--29.9 (Overweight)5436(34.9)3449(63.2)3836(70.8)1126(20.4)-- 30.0+ (Obese)5627(36.4)3390(60.1)4422(78.7)1722(30.4)--Manipulative Methods Yes3778(24.3)2492(65.7)2678(71.1)762(20.2)1425(38.0) No11,685(75.7)6997(59.6)8620(73.8)2766(23.4)4202(35.9)Mind-Body Interventions Yes801(5.1)497(62.0)518(64.9)88(11.4)220(27.7) No14,662(94.9)8992(61.1)10,780(73.6)3440(23.2)5407(36.9)Biological Treatments Yes42(0.3)24(58.7)32(76.2)7(15.9)11(27.0) No15,421(99.7)9465(61.1)11,266(73.2)3521(22.6)5616(36.4)Energy Therapies Yes72(0.5)49(67.3)38(51.8)11(14.5)29(39.1) No15,391(99.5)9440(61.1)11,260(73.3)3517(22.6)5598(36.4)Alternative Systems Yes592(3.8)395(66.9)394(66.6)97(16.5)204(34.8) No14,871(96.2)9094(60.9)10,904(73.4)3431(22.8)5423(36.5)Note: All frequencies are unweighted; all percentages are weightedTable 2Proportions and odds of CAM use among adults with and without comorbiditiesIndependent VariablesOverall CAM UseCAM Use in Patients with\
2 or More Chronic ConditionsAdjusted Odds of CAM UsePatients with\
1 Chronic ConditionPatients with\
2 or More Chronic Conditionsn(%)*χ*^*2*^, *p*-valuen(%)*χ*^*2*^, *p*-valueaOR \[95% CI\]*p*-valueaOR \[95% CI\]*p*-valueAge Group6.69, *p* \< 0.00114.04, *p* = 0.003  \< 35 (ref)349(28.3)156(26.9)1.00--1.00-- 35--49887(29.9)473(27.7)1.12\[0.89,1.39\]0.3311.04\[0.83,1.30\]0.729 50--641740(31.6)1108(31.0)1.07\[0.86,1.32\]0.5481.21\[0.98,1.49\]0.083  \> 641607(27.6)1042(27.4)0.94\[0.75,1.18\]0.5291.10\[0.88,1.37\]0.417Sex3.28, *p* = 0.0712.29, *p* = 0.130 Male (ref)1999(28.7)1219(28.0)1.00--1.00-- Female2584(30.2)1560(29.4)1.25\[1.11,1.42\]\< 0.0011.29\[1.17,1.42\]\< 0.001Race and Ethnicity79.11, *p* \< 0.001161.97, *p* \< 0.001 Non-Hispanic White (ref)3857(32.9)2307(32.0)1.00--1.00-- Non-Hispanic Black/African American460(16.4)320(17.2)0.46\[0.37,0.56\]\< 0.0010.52\[0.45,0.60\]\< 0.001 Alaska Natives/American Indians39(25.2)24(22.4)0.98\[0.52,1.85\]0.9490.64\[0.40,1.02\]0.058 Non-Hispanic Other227(25.6)128(25.8)0.61\[0.47,0.78\]\< 0.0010.75\[0.60,0.94\]0.012Education Level111.49, *p* \< 0.001132.62, *p* \< 0.001 Less than High School (ref)533(18.8)369(19.1)1.00--1.00-- High School Graduate/Some College2696(30.0)1694(29.6)1.80\[1.48,2.19\]\< 0.0011.53\[1.34,1.74\]\< 0.001 College/Professional Graduate1354(36.5)716(35.3)2.12\[1.70,2.65\]\< 0.0011.78\[1.51,2.09\]\< 0.001Marital Status12.49, *p* \< 0.00116.36, *p* \< 0.001 Married (ref)2550(31.2)1533(30.2)1.00--1.00-- Widowed/Divorced1465(28.3)919(28.0)1.04\[0.90,1.21\]0.5891.02\[0.92,1.15\]0.666 Single/Never Married568(25.9)327(24.8)0.96\[0.79,1.16\]0.6810.92\[0.79,1.07\]0.291Family Income38.48, *p* \< 0.00197.68, *p* \< 0.001  \< \$20,000 (ref)1652(24.7)1097(24.6)1.00--1.00-- \$20,000--\$34,999613(29.0)367(27.3)1.12\[0.93,1.36\]0.2450.98\[0.85,1.14\]0.838 \$35,000--\$49,999801(34.3)483(34.3)1.21\[1.00,1.46\]0.0441.30\[1.12,1.50\]\< 0.001 \$50,000--\$74,9991255(36.2)675(35.1)1.21\[1.01,1.46\]0.0401.25\[1.08,1.44\]0.003 \$75,000+262(28.6)157(29.1)1.01\[0.78,1.32\]0.9311.14\[0.93,1.41\]0.208Health Insurance Coverage4.31, *p* = 0.0390.05, *p* = 0.816 Yes4107(29.8)2489(28.8)1.05\[0.85,1.29\]0.6740.84\[0.71,0.99\]0.041 No (ref)476(27.2)290(28.4)1.00--1.00--Regular Source of Care9.36, *p* = 0.0027.02, *p* = 0.008 Yes4256(29.9)2624(29.0)1.06\[0.86,1.31\]0.5961.09\[0.88,1.35\]0.424 No (ref)327(25.3)155(24.1)1.00--1.00--Geographic Region33.08, *p* \< 0.001157.90, *p* \< 0.001 Northeast (ref)702(27.3)389(25.0)1.00--1.00-- Midwest1140(35.6)723(35.8)1.21\[1.00,1.46\]0.0461.64\[1.41,1.90\]\< 0.001 South1441(24.1)895(23.1)0.91\[0.76,1.08\]0.2681.03\[0.89,1.19\]0.681 West1300(34.4)772(34.6)1.21\[1.01,1.45\]0.0371.61\[1.38,1.87\]\< 0.001Hypercholesterolemia45.22, *p* \< 0.00113.64, *p* \< 0.001 Yes2995(31.5)2105(29.7) No1588(26.4)674(25.9)Hypertension27.19, *p* \< 0.0010.33, *p* = 0.566 Yes3210(28.3)2357(28.6) No1373(32.7)422(29.4)Diabetes41.12, *p* \< 0.00125.62, *p* \< 0.001 Yes877(25.0)814(25.4) No3706(30.8)1965(30.4)Body Mass Index12.01, *p* \< 0.00122.60, *p* \< 0.001  \< 18.5 (Underweight)158(1.0)67(19.8) 18.5--24.9 (Normal)1092(7.0)338(25.6) 25.0--29.9 (Overweight)1669(10.7)712(29.6) 30.0+ (Obese)1664(10.8)1662(29.6)Note: All frequencies are unweighted; all percentages are weightedTable 3Utilization of CAM modalities by chronic disease dyads and triadsDisease CombinationsOverall CAM Use\
(n = 15,463)CAM ModalitiesManipulative Methods\
(*n* = 3778)Biological Treatments\
(*n* = 42)Mind-Body Interventions\
(*n* = 801)Energy Therapies\
(*n* = 72)Alternative Systems\
(*n* = 592)(%)*χ*^*2*^ value, *p*-value*(%)χ*^*2*^ value, *p*-value(%)*χ*^*2*^ value, *p*-value*(%)χ*^*2*^ value, *p*-value*(%)χ*^*2*^ value, *p*-value*(%)χ*^*2*^ value, *p*-valueDisease DyadsChoBp0.08, *p* = 0.7735.12, *p* = 0.0240.03, *p* = 0.87230.13, *p* \< 0.0015.32, *p* = 0.0221.02, *p* = 0.314 Yes11.225.40.33.90.33.6 No18.323.70.35.90.64.0ChoDiab6.15, *p* = 0.0140.58, *p* = 0.4470.25, *p* = 0.61429.25, *p* \< 0.0014.16, *p* = 0.0422.83, *p* = 0.094 Yes3.823.70.22.60.23.1 No25.724.40.35.60.53.9ChoOb10.53, *p* = 0.00122.79, *p* \< 0.0011.27, *p* = 0.26118.55, *p* \< 0.0012.64, *p* = 0.1061.40, *p* = 0.238 Yes6.927.40.23.70.74.1 No22.623.50.35.60.43.7BpDiab17.18, *p* \< 0.0014.51, *p* = 0.0350.15, *p* = 0.70237.98, *p* \< 0.0014.78, *p* = 0.0304.88, *p* = 0.028 Yes4.322.70.22.60.23.0 No25.224.60.35.70.54.0BpOb0.05, *p* = 0.8272.61, *p* = 0.1071.67, *p* = 0.19714.34, *p* \< 0.0012.68, *p* = 0.1033.03, *p* = 0.083  Yes8.425.10.24.00.33.4  No21.124.00.35.60.54.0DiabOb8.55, *p* = 0.0042.01, *p* = 0.1575.69, *p* = 0.01827.74, *p* \< 0.0011.56, *p* = 0.2122.43, *p* = 0.120  Yes2.922.90.042.40.33.1  No26.624.50.35.50.53.9Disease TriadsChoBpDiab2.84, *p* = 0.0930.04, *p* = 0.8340.01, *p* = 0.93322.67, *p* \< 0.0013.74, *p* = 0.0541.08, *p* = 0.299  Yes3.2024.10.32.60.23.3  No26.324.30.35.50.53.9ChoBpOb5.13, *p* = 0.02413.43, *p* \< 0.0012.68, *p* = 0.10214.78, *p* \< 0.0010.42, *p* = 0.5180.02, *p* = 0.884  Yes4.927.20.13.60.43.8  No24.623.80.35.40.53.8ChoDiabOb0.37, *p* = 0.5440.28, *p* = 0.5962.82, p = 0.09418.48, *p* \< 0.0011.30, *p* = 0.2550.40, *p* = 0.528  Yes2.025.00.02.20.23.5  No27.524.30.35.40.53.8BpDiabOb4.34, *p* = 0.0380.48, *p* = 0.4913.89, *p* = 0.05018.99, *p* \< 0.0012.28, *p* = 0.1321.04, *p* = 0.309  Yes2.323.50.12.50.23.3  No27.224.40.35.40.53.9Note: All percentages are weighted proportionsDisease Dyads: ChoBp = Hypercholesterolemia and Hypertension; ChoDiab = Hypercholesterolemia and Diabetes; ChoOb = Hypercholesterolemia and Obesity; BpDiab = Hypertension and Diabetes; BpOb = Hypertension and Obesity; DiabOb = Diabetes and ObesityDisease Triads: ChoBpDiab = Hypercholesterolemia and Hypertension and Diabetes; ChoBpOb = Hypercholesterolemia and Hypertension and Obesity; BpDiabOb = Hypertension and Diabetes and Obesity; ChoDiabOb = Hypercholesterolemia and Diabetes and Obesity

Sample characteristics {#Sec7}
----------------------

As described in Table [1](#Tab1){ref-type="table"}, the sample was predominately White (75.6%), with the Southern region of the U.S. represented approximately twice the proportion of each of the other regions. Approximately 55.1% were female, 52.7% were married, and 73.2% were 50 years of age or older. About 76% had a high school or less education, and about one-quarter had graduated from college. Hypertension was most prevalent (73.2%), followed by hypercholesterolemia (61.1%), obesity (36.4%), and diabetes (22.6%). Approximately 37.2% of the participants had just one of the four chronic conditions, while 62.4% had more than one chronic disease.

Bivariate and multivariate analysis of CAM use {#Sec8}
----------------------------------------------

### Bivariate analysis {#Sec9}

As noted in Fig. [1](#Fig1){ref-type="fig"}, overall 29.5% of the sample reported use of CAM of any kind. However, an examination of CAM use by disease status (see Table [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}) showed lower proportions of participants with hypertension (28.3%), diabetes (25.0%), or obesity (10.8%) used CAM compared to those without these conditions (*p \< 0.001*). Participants with hypercholesterolemia (31.5%) showed higher proportions of CAM use compared to those without this condition (*p \< 0.001*). All the covariates except for sex were statistically associated with CAM use *(p \< 0.05*). Additional results from the multivariate logistic regression analysis are reported in Table [2](#Tab2){ref-type="table"} with aORs controlling for potential confounding effects of the covariates in the model (e.g., education, sex, race/ethnicity, insurance status, etc.).Fig. 1Overall and Individual Disease-Specific Rates of CAM Use. Overall: \[Yes = Used CAM of any kind regardless of disease condition; No = Did not use CAM\]; For individual disease conditions: \[Yes = Used CAM and had the disease; No = Used CAM but did not have the disease\]; Significance levels: \**p \< 0.05*, \*\**p \< 0.01*, \*\*\**p \< 0.001*

### Multivariate analysis: Participants with one chronic condition {#Sec10}

After controlling for confounding effects for those with one chronic condition, females were 25% more likely to use CAM than males (*p \< 0.001*). Black/African Americans and the Non-Hispanic Other group were 54% and 39% less likely to report CAM use compared to Whites (*p \< 0.001*), respectively. Compared to individuals with less than a high school education, high school and college graduates were 80% and 2.12 times more likely to report CAM use, respectively (*p \< 0.001*). Participants with incomes in the range \$35,000 to \$49,999 or \$50,000 to \$74,999 were each 21% more likely to report CAM use compared to those with incomes less than \$20,000 per year (*p \< 0.05*). Finally, there was a 21% increased likelihood of using CAM for those participants residing in the Midwest or West, respectively, compared to Northeast residents (*p \< 0.05*). For those with one chronic condition, there was no significant relationship in the adjusted odds of CAM use by age, marital status, having health insurance, or having a regular source of care.

### Multivariate analysis: Participants with two or more chronic conditions {#Sec11}

After adjusting for potential confounders for those with two or more chronic conditions, age, marital status, and having a regular source of care had no statistically significant effect on CAM use. Compared to Non-Hispanic Whites, Black/African Americans were 48% less likely to use CAM (*p \< 0.001*), while Non-Hispanic Others were 25% less likely to report CAM use (*p \< 0.05*). Those with health insurance and two or more conditions were 16% less likely to report CAM use compared to those without health insurance and two or more conditions (*p \< 0.05*). Females were 29% more likely to report CAM use compared to males (*p \< 0.001*).

Residents of the Midwest were 64% more likely to report CAM use (*p \< 0.001*), while those from the West were 61% more likely to use CAM (*p \< 0.001*), compared to those living in the Northeast. Compared to individuals with less than a high school education, high school and college graduates were 53% and 78% significantly more likely to report CAM use, respectively (*p \< 0.001*). Finally, compared to participants making less than \$20,000, participants with income ranges of \$35,000 to \$49,999 and \$50,000 to \$74,999 were 30% (*p \< 0.001*) and 25% (*p \< 0.01*) more likely to use CAM.

### Multivariate analysis: CAM use by disease dyads and triads {#Sec12}

Table [3](#Tab3){ref-type="table"} summarizes the proportions of CAM use by disease dyads and disease triads with respect to overall utilization and the specific CAM domains as operationally defined in this study. Diabetes co-occurring with hypercholesterolemia, hypertension, or obesity was significant for overall CAM use with rates ranging from 2.9 to 4.3% (*p \< 0.05*). Those without these comorbidities using CAM had rates of 25.2% to 26.6%. Similarly, having both hypercholesterolemia and obesity yielded a significantly lower rate (6.9%) of CAM use compared to 22.6% among those using CAM who did not have this disease combination (*p \< 0.01*). However, two disease dyads were not significant for CAM use among those with and without the disease combinations (i.e., hypertension and hypercholesterolemia; and hypertension and obesity). However, disease concordance with some of the highest proportions of CAM use (11.2% and 8.4%, respectively) was observed among persons within each of these groups, as noted in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2CAM Use by Disease Dyads. \[Yes = Used CAM and had the disease dyad; No = Used CAM but did not have the disease dyad\]; Disease Dyads: ChoBp = Hypercholesterolemia and Hypertension; ChoDiab = Hypercholesterolemia and Diabetes; ChoOb = Hypercholesterolemia and Obesity; BpDiab = Hypertension and Diabetes; BpOb = Hypertension and Obesity; DiabOb = Diabetes and Obesity; Significance levels: \**p \< 0.05*, \*\**p \< 0.01*, \*\*\**p \< 0.001*

Across the disease triads, as noted in Table [3](#Tab3){ref-type="table"}, proportions of CAM use ranged from 2.0 to 4.9% for those with these comorbidities. However, as reflected in Fig. [3](#Fig3){ref-type="fig"}, with respect to disease triads, only two of the four triads (hypertension and obesity co-occurring with either hypercholesterolemia or diabetes) were significant (*p \< 0.05*). Nearly 5% of persons with hypertension, obesity, and hypercholesterolemia reported CAM use compared to 24.6% who used CAM but did not have this disease combination (*p \< 0.05*). Similarly, having hypertension, obesity, and diabetes was also significant for CAM use (2.3%) compared to 27.2% who did not have these conditions but used CAM (*p \< 0.05*).Fig. 3CAM Use by Disease Triads. \[Yes = Used CAM and had the disease triad; No = Used CAM but did not have the disease triad\]; Disease Triads: ChoBpDiab = Hypercholesterolemia and Hypertension and Diabetes; ChoBpOb = Hypercholesterolemia and Hypertension and Obesity; ChoDiabOb = Hypercholesterolemia and Diabetes and Obesity; BpDiabOb = Hypertension and Diabetes and Obesity; Significance levels: \**p \< 0.05*, \*\**p \< 0.01*, \*\*\**p \< 0.001*

After adjusting for potential confounders for those with two or more chronic conditions, for the six dyad combinations (see Table [4](#Tab4){ref-type="table"}), significant results for the adjusted odds ratios were only found for obese diabetic participants, who were 30% less likely to use CAM compared to those without these two chronic conditions (aOR = 0.70; 95% CI:0.55--0.88; *p \< 0.01*). For the four disease triad combinations, significantly higher adjusted odds were only found for those participants with a concurrent diagnosis of hypercholesterolemia, diabetes, and obesity, who were 41% more likely to use CAM compared to those without these three chronic conditions (aOR = 1.41; 95% CI:1.02--1.94; *p \< 0.05*). Additionally, those with hypercholesterolemia, hypertension, and obesity were 22% more likely to use CAM compared to those without these three comorbidities (aOR = 1.22; 95% CI:1.09--1.36; *p \< 0.01*).Table 4Odds of CAM use among adults by chronic disease dyads and triadsDisease CombinationsAdjusted Odds of CAM UseaOR \[95% CI\]p-valueDisease DyadsChoBp No (ref)1.04\[0.95--1.14\]0.351 Yes1.00--ChoDiab No (ref)0.92\[0.75--1.11\]0.368 Yes1.00--ChoOb No (ref)1.08\[0.96--1.21\]0.210 Yes1.00--BpDiab No (ref)1.06\[0.91--1.24\]0.451 Yes1.00--BpOb No (ref)1.05\[0.96--1.15\]0.309 Yes1.00--DiabOb No (ref)0.70\[0.55--0.88\]0.003 Yes1.00--Disease TriadsChoBpDiab No (ref)1.00-- Yes1.11\[0.94--1.32\]0.210ChoBpOb No (ref)1.00-- Yes1.22\[1.09--1.36\]0.001ChoDiabOb No (ref)1.00-- Yes1.41\[1.02--1.94\]0.037BpDiabOb No (ref)1.00-- Yes0.83\[0.67--1.03\]0.083Disease Dyads: ChoBp = Hypercholesterolemia and Hypertension; ChoDiab = Hypercholesterolemia and Diabetes; ChoOb = Hypercholesterolemia and Obesity; BpDiab = Hypertension and Diabetes; BpOb = Hypertension and Obesity; DiabOb = Diabetes and ObesityDisease Triads: ChoBpDiab = Hypercholesterolemia and Hypertension and Diabetes; ChoBpOb = Hypercholesterolemia and Hypertension and Obesity; BpDiabOb = Hypertension and Diabetes and Obesity; ChoDiabOb = Hypercholesterolemia and Diabetes and Obesity

### Multivariate analysis: CAM domain use by disease status {#Sec13}

Across all four individual chronic conditions, manipulative methods had the highest rates of use (22--26%, *p \< 0.05*). Alternative medical systems were also used by those with hypertension, hypercholesterolemia, or diabetes (3--4%, *p \< 0.01*). For those with hypertension, diabetes, or obesity, approximately 3% to 5% used mind-body interventions (*p \< 0.001*). Use of energy therapies (0.3%, *p \< 0.001*) was only significant for those with hypertension, while use of biological treatments was not significant for any individual chronic condition. In general, the evidence suggests that there is greater use of manipulative methods, alternative medical systems, and mind-body interventions among participants with these individual chronic conditions. In addition, participants with hypertension utilized the greatest variety of treatments with significant usage across four of the five CAM domains, followed by participants with diabetes significantly utilizing treatments within three of the five CAM domains. Alternatively, participants with hypercholesterolemia or obesity significantly used CAM treatments within just two of the five CAM domains.

As noted in Table [3](#Tab3){ref-type="table"}, there appears to be higher use of mind-body interventions and manipulative methods among participants with two comorbidities. Whereas mind-body interventions are consistently and statistically associated with all six disease dyads with utilization ranging from 2 to 4% (*p \< 0.001*), manipulative methods were significant for three dyads with the highest proportions overall (23--27%, *p \< 0.05*). The use of energy therapies was also significant for three of the disease dyads, but with lower proportions (0.2--0.3%, *p \< 0.05*). The use of alternative medical systems was significant for just one disease dyad (3%, *p \< 0.05*), as was the use of biological treatments (0.04%, *p \< 0.05*). In the dyad participant populations, those with hypertension and diabetes utilized the greatest variety of treatments with significant usage across four of the five CAM domains, followed by participants with hypertension and hypercholesterolemia significantly utilizing treatments within three of the five CAM domains. Alternatively, participants with hypercholesterolemia and either diabetes or obesity, as well as obese diabetic participants significantly used treatments within two of the five CAM domains. Finally, obese hypertensive participants significantly used treatments within just one CAM domain.

Similar to the findings in the disease dyads, the use of mind-body interventions was significant (*p \< 0.001*) across all disease triads with proportions ranging from 2 to 4%. However, the use of manipulative methods was only significant for persons with hypercholesterolemia, hypertension, and obesity (*p \< 0.001*), with a large proportion of use (27%) for this group. The use of biological treatments, energy therapies, and alternative medical systems were not significant for any of the disease triads, with use trends all under 4%. In the triad participant populations, those with hypertension, hypercholesterolemia, and obesity utilized the greatest variety of treatments with significant usage across two of the five CAM domains, whereas all other triad participants significantly utilized treatments within just one of the five CAM domains.

Discussion {#Sec14}
==========

An alternate study based on 2012 NHIS adult respondents with and without mental illness and two or more chronic physical conditions (including diabetes, hyperlipidemia, hypertension, and others) \[[@CR17]\], similarly found higher patterns of CAM use across manipulative methods (15%) compared to mind-body interventions (6%) or alternative medical systems (4%) for those with physical comorbidities only. Manipulative methods, in particular, may appeal to users that prefer collaborative decision making with a supportive CAM practitioner \[[@CR18]\]. Other researchers have documented that such therapeutic relationships can occur irrespective of the CAM treatment efficacy \[[@CR5]\].

The observed diminished effect of disease triads on overall use of CAM as well as less use of specific modalities may reflect the fact that when individuals have more than two comorbidities, they are likely to be under strict care and management by a conventional health care provider. As such, these patients are likely to be on pharmaceutical agents or intentionally minimizing use of CAM products. With respect to manipulative methods, it is possible that patients with three chronic conditions are in such a debilitated state that engagement with these methods may not be possible.

Limitations {#Sec15}
-----------

Before discussing further implications of this study, several limitations must be noted. First, self-reported NHIS data are based on a sample of the population, and thus this study may be affected by sampling error and missing data. Second, CAM use trends may have changed since the publication of NHIS 2012 data set. In addition, the self-reported nature of the survey may have resulted in under-reporting of the various chronic diseases and CAM use. Nonetheless, the cross-sectional nature of the study allowed us to examine associations among sociodemographic factors, disease conditions, and use of a myriad of CAM therapies.

Implications for family practitioners {#Sec16}
-------------------------------------

This study has implications for the management of patients with chronic conditions, especially when these ailments co-exist. In this study, as summarized in Table [5](#Tab5){ref-type="table"}, two CAM modalities (i.e., mind-body interventions and manipulative methods) dominated use patterns of participants with individual chronic conditions, as well as with disease dyads and triads composed of hypercholesterolemia, hypertension, diabetes, and obesity. These modalities have little interference and minimal to no side effects with conventional medicines that may be prescribed for these conditions. Alternatively, for some chronic diseases, alternative medical systems (3 individual disease conditions and 1 dyad), energy therapies (1 individual disease condition and 3 dyads), and biological treatments (1 dyad) were also significant choices for some participants.Table 5Statistically Significant CAM Modality Use by Disease StatusMIND-BODY INTERVENTIONSMANIPULATIVE METHODSHypertension\*\*\*\
Diabetes\*\*\*\
Obesity\*\*\*ChoBp\*\*\*\
ChoDiab\*\*\*\
ChoOb\*\*\*\
BpDiab\*\*\*\
BpOb\*\*\*\
DiabOb\*\*\*ChoBpDiab\*\*\*\
ChoBpOb\*\*\*\
ChoDiabOb\*\*\*\
BpDiabOb\*\*\*Hypercholesterolemia\*\*\*\
Hypertension\*\*\
Diabetes\*\*\*\
Obesity\*ChoBp\*\
ChoOb\*\*\*\
BpDiab\*ChoBpOb\*\*\*ALTERNATIVE SYSTEMSENERGY THERAPIESHypercholesterolemia\*\* Hypertension\*\*\*\
Diabetes\*\*BpDiab\*Hypertension\*\*\*ChoBp\*\
ChoDiab\*\
BpDiab\*BIOLOGICAL TREATMENTSDiabOb\*Disease Dyads: ChoBp = Hypercholesterolemia and Hypertension; ChoDiab = Hypercholesterolemia and Diabetes; ChoOb = Hypercholesterolemia and Obesity; BpDiab = Hypertension and Diabetes; BpOb = Hypertension and Obesity; DiabOb = Diabetes and ObesityDisease Triads: ChoBpDiab = Hypercholesterolemia and Hypertension and Diabetes; ChoBpOb = Hypercholesterolemia and Hypertension and Obesity; BpDiabOb = Hypertension and Diabetes and Obesity; ChoDiabOb = Hypercholesterolemia and Diabetes and ObesitySignificance levels: \**p \< 0.05*, \*\**p \< 0.01*, \*\*\**p \< 0.001*

Conclusions {#Sec17}
===========

As integrative medicine becomes commonplace, family practitioners will play a pivotal role in educating patients on the benefits and potential harm of CAM products \[[@CR19], [@CR20]\]. This is especially true as more patients require maintenance medications that may increase the risk for multi-drug or herb-drug interactions or nullify the sometimes narrowly windowed therapeutic effects of the pharmaceutical agents indicated for these conditions \[[@CR7], [@CR21]\]. Our study provides prevalence data concerning the use of CAM modalities among persons with a variety of chronic condition dyads and triads, and these disease combinations have gone largely understudied in the scientific literature with respect to specific CAM domain usage rates. Patients with multiple comorbidities use various non-conventional approaches, and as such, it is important for health care providers at every level to proactively probe patients on the use of CAM products and or services and to offer personalized information about the possible risks, benefits, and potential implications of using CAM. Indeed, research has consistently shown patients do not always voluntarily divulge information on CAM use to providers \[[@CR5], [@CR22], [@CR23]\]. This study focused on four chronic conditions due to their prevalence in the general population. As clinical practice guidelines and life-style recommendations for multimorbid patients continue to be developed to include CAM, future research on these and other comorbidities may contribute to improved health care utilization and patient outcomes.

aOR

:   Adjusted odds ratio

CAM

:   Complementary and alternative medicine

CI

:   Confidence interval

NCHS

:   National Center for Health Statistics

NHIS

:   National Health Interview Survey

OR

:   Odds ratio

The datasets analyzed during the current study are available in the National Health Interview Survey repository \[<https://www.cdc.gov/nchs/nhis>\] \[[@CR13]\].
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